Zacks Investment Research Lowers ABLYNX (ABLYF) to Hold

ABLYNX (OTCMKTS:ABLYF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “

Separately, Bank of America started coverage on shares of ABLYNX in a research report on Friday, November 10th. They issued a “buy” rating and a $26.00 price target on the stock.

Shares of ABLYNX (ABLYF) opened at $38.48 on Friday. ABLYNX has a 1 year low of $11.10 and a 1 year high of $50.00.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.themarketsdaily.com/2018/01/14/zacks-investment-research-lowers-ablynx-ablyf-to-hold.html.

About ABLYNX

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.

Get a free copy of the Zacks research report on ABLYNX (ABLYF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply